Avadel Pharmaceuticals (AVDL) EPS (Basic): 2009-2021
Historic EPS (Basic) for Avadel Pharmaceuticals (AVDL) over the last 6 years, with Dec 2021 value amounting to -$0.39.
- Avadel Pharmaceuticals' EPS (Basic) fell 71.60% to -$0.39 in Q4 2021 from the same period last year, while for Dec 2021 it was -$1.51, marking a year-over-year decrease of 153.78%. This contributed to the annual value of -$1.46 for FY2021, which is 1222.56% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its EPS (Basic) stood at -$0.39 for Q4 2021, which was up 9.88% from -$0.44 recorded in Q3 2021.
- Avadel Pharmaceuticals' 5-year EPS (Basic) high stood at $0.70 for Q2 2017, and its period low was -$1.71 during Q4 2018.
- Moreover, its 3-year median value for EPS (Basic) was -$0.23 (2019), whereas its average is -$0.25.
- As far as peak fluctuations go, Avadel Pharmaceuticals' EPS (Basic) surged by 520.00% in 2017, and later slumped by 850.00% in 2018.
- Quarterly analysis of 5 years shows Avadel Pharmaceuticals' EPS (Basic) stood at -$0.18 in 2017, then slumped by 850.00% to -$1.71 in 2018, then soared by 95.91% to -$0.07 in 2019, then plummeted by 228.57% to -$0.23 in 2020, then crashed by 71.60% to -$0.39 in 2021.
- Its EPS (Basic) stands at -$0.39 for Q4 2021, versus -$0.44 for Q3 2021 and -$0.40 for Q2 2021.